Gut bacteria in health and disease

Gastroenterology and Hepatology

Volumn 9, Issue 9, 2013, Pages 560-569

  Quigley, Eamonn M M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Gut bacteria; Gut flora; Microbial metabolism; Microbiota; Mucosal immunology; Probiotic

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; ENTERITIS; HOST; IMMUNE SYSTEM; INTESTINE FLORA; IRRITABLE COLON; LABORATORY TEST; MEDICINE; METABOLIC SYNDROME X; MICROBIAL COLONIZATION; MICROBIAL COMMUNITY; MICROFLORA; MICROORGANISM; NONALCOHOLIC FATTY LIVER; OBESITY; TREATMENT PLANNING;

EID: 84887851957     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512-519.
2. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859-904.
3. Marques TM, Wall R, Ross R P, Fitzgerald G F, Ryan CA, Stanton C. Programming inflant gut microbiota: infiuence of dietary and environmental factors. Curr Opin Biotechnol. 2010;21(2):149-156.
4. Fouhy F, Ross R P, Fitzgerald G F, Stanton C, Cotter PD. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of highthroughput sequencing to address these gaps.. Gut Microbes. 2012;3(3):203-220.
5. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
6. Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab. 2011;58(suppl 2):44-52.
7. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-1638.
8. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human inflant intestinal microbiota. PLoS Biol. 2007;5(7):e177.
9. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing inflant gut microbiome. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4578-4585.
10. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-180.
11. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148(6):1258-1270.
12. Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123.
13. O'Toole PW, Claesson MJ. Gut microbiota: changes throughout the lifespan from inflancy to elderly. Int Dairy J. 2010;20(4):281-291.
14. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178-184.
15. O'Hara AM, Shanahan F. The gut fora as a forgotten organ. EMBO Rep. 2006;7(7):688-693.
16. Ryan KA, Jayaraman T, Daly P, et al. Isolation of lactobacilli with probiotic properties from the human stomach. Lett Appl Microbiol. 2008;47(4):269-274.
17. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminaland mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-G807.
18. Swidsinski A, Weber J, Loening-Baucke V, Hale L P, Lochs H. Spatial organization and composition of the mucosal fora in patients with inflammatory bowel disease.. J Clin Microbiol. 2005;43(7):3380-3389.
19. Ley RE, Lozupone CA, Hamady M, Knight R, Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008;6(10):776-778.
20. Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes. 2010;1(4):279-284.
21. Patel RM, Lin P W. Developmental biology of gut-probiotic interaction. Gut Microbes. 2010;1(3):186-195.
22. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know about gnotobiology.. Microbiol Mol Biol Rev. 1998;62(4):1157-1170.
23. Uribe A, Alam M, Johansson O, Midtvedt T, Teodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology. 1994;107(5):1259-1269.
24. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(5):107-118.
25. Konieczna P, Groeger D, Ziegler M, et al. Bifidobacterium inflantis 35624 administration induces Foxp3+ 1 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells.. Gut. 2012;61(3):354-366.
26. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;452(7203):428-435.
27. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens.. Nat Rev Microbiol. 2010;8(3):171-184.
28. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of I?B-a ubiquitination. Science. 2000;289(5484):1560- 1563.
29. O'Mahony C, Scully P, O'Mahony D, et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation.. PLoS Pathog. 2008;4(8):e1000112.
30. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010;330(6012):1768-1773.
31. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro T T, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A. 2010;107(1):454-459.
32. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002;16(6):915-931.
33. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the anti-infective activity of Lactobacillus salivarius UCC118.. Proc Natl Acad Sci U S A. 2007;104(18):7617-7621.
34. Rea MC, Sit CS, Clayton E, et al. Turicin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difcile.. Proc Natl Acad Sci U S A. 2010;107(20):9352-9357.
35. O'Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol. 2007;5(3):274-284.
36. Castagliuolo I, Riegler M F, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difcile toxins A and B in human colonic mucosa.. Infect Immun. 1999;67(1):302-307.
37. Jones B V, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome.. Proc Natl Acad Sci U S A. 2008;105(36):13580-13585.
38. Claesson MJ, O'Toole P W. Evaluating the latest high-throughput molecular techniques for the exploration of microbial gut communities.. Gut Microbes. 2010;1(4):277-278.
39. Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol. 2012;9(6):312-322.
40. Saulnier DM, Santos F, Roos S, et al. Exploring metabolic pathway reconstruction and genome-wide expression profiling in Lactobacillus reuteri to define functional probiotic features.. PLoS One. 2011;6(4):e18783.
41. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26(1):5-11.
42. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Review article: bifidobacteria as probiotic agents-physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005;22(6):495-512.
43. Lesniewska V, Rowland I, Laerke HN, Grant G, Naughton PJ. Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo.. Exp Physiol. 2006;91(1):229-237.
44. Wang B, Mao Y-K, Diorio C, et al. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes.. FASEB J. 2010;24(10):4078-4088.
45. Heijtz RD, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011;108(7):3047-3052.
46. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011;23(3):255-264.
47. Cryan J F, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23(3):187-192.
48. Fleshner M. The gut microbiota: a new player in the innate immune stress response? Brain Behav Immun. 2011;25(3):395-396.
49. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.. Proc Natl Acad Sci U S A. 2011;108(38):16050-16055.
50. Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep. 2007;9(6):497-507.
51. Shanahan F. The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. Nutr Rev. 2012;70(suppl 1):S31-S37.
52. Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53(11):1602-1609.
53. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126(5):1358-1373.
54. Tomas CM, Versalovic J. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes. 2010;1(3):148-163.
55. Isolauri E, Salminen S. Probiotics, gut inflammation and barrier function. Gastroenterol Clin North Am. 2005;34(3):437-450.
56. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double-blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokines.. Gut. 2003;52(7):975-980.
57. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.. Gastroenterology. 2004;126(2):520-528.
58. Sheil B, McCarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis.. Gut. 2004;53(5):694-700.
59. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012;3(6):544-555.
60. Sokol H, Seksik P, Furet J P, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15(8):1183-1189.
61. Van Limbergen J, Philpott D, Griffiths AM. Genetic profiling in inflammatory bowel disease: from association to bedside. Gastroenterology. 2011;141(5):1566-1571.
62. Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.. Curr Gastroenterol Rep. 2006;8(6):486-498.
63. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.. Aliment Pharmacol Ther. 1997;11(5):853-858.
64. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.. Lancet. 1999;354(9179):635-639.
65. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22(1):56-63.
66. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.. Gut. 2004;53(11):1617-1623.
67. Zocco MA, Dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567-1574.
68. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.. Aliment Pharmacol Ther. 2004;20(10):1133-1141.
69. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15(6):697-698.
70. Bibiloni R, Fedorak RN, Tannock G W, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100(7):1539-1546.
71. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal fora. J Clin Gastroenterol. 2010;44(8):551-561.
72. Guo B, Harstall C, Louie T, Veldhuyzen Van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difcile-associated disease.. Aliment Pharmacol Ther. 2012;35(8):865-875.
73. Borody TJ, Warren E F, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37(1):42-47.
74. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107(10):1452-1459.
75. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.. Gut. 2004;53(1):108-114.
76. Ghoshal UC, Shukla R, Ghoshal U, et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085.
77. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome.. J Neurogastroenterol Motil. 2012;18(3):258-268.
78. Quigley EM. A 51-year-old with IBS: test or treat for bacterial overgrowth? Clin Gastroenterol Hepatol. 2007;5(10):1140-1143.
79. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
80. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.. Gastroenterology. 2005;128(3):541-551.
81. Konieczna P, Akdis CA, Quigley EM, Shanahan F, O'Mahony L. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes. 2012;3(3):261-266.
82. Jeffery IB, Quigley EM, Öhman L, Simrén M, O'Toole P W. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes. 2012;3(6):572-576.
83. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2010;55(2):392-397.
84. Jeffery IB, O'Toole P W, Ohman L, et al. An irritable bowel syndrome subtype defined by species-speciffic alterations in faecal microbiota. Gut. 2012;61(7):997-1006.
85. Quigley EM. Bacteria: a new player in gastrointestinal motility disorders-infections, bacterial overgrowth, and probiotics.. Gastroenterol Clin North Am. 2007;36(3):735-748.
86. Quigley EM, Flourie B. Probiotics in irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.. Neurogastroenterol Motil. 2007;19(3):166-172.
87. Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal gut fora and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100(11):2560-2568.
88. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacterium inflantis: an assessment of potential antidepressant properties in the rat.. J Psychiatr Res. 2008;43(2):164-174.
89. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan J F, Dinan TG. Effects of the probiotic Bifidobacterium inflantis in the maternal separation model of depression. Neuroscience. 2010;170(4):1179-1188.
90. McKernan D P, Fitzgerald P, Dinan TG, Cryan J F. The probiotic Bifidobacterium inflantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil. 2010;22(9):1029-1035.
91. Zeng J, Li Y-Q, Zuo X-L, Zhen Y-B, Yang J, Liu C-H. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.. Aliment Pharmacol Ther. 2008;28(8):994-1002.
92. Rousseaux C, Turu X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35-37.
93. Verdu E F, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction.. Gastroenterology. 2004;127(3):826-837.
94. Verdu E F, Bercik P, Verma-Gandhu M, et al. Speciffic probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182-190.
95. Kamiya T, Eang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.. Gut. 2006;55(2):191-196.
96. Valeur N, Engel P, Carbajal N, Connolly E, Ladefioged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract.. Appl Environ Microbiol. 2004;70(2):1176-1181.
97. Duncker SC, Wang L, Hols P, Bienenstock J. The D-alanine content of lipotechoic acid is crucial for Lactobacillus plantarum-mediated protection from visceral pain perception in a rat colorectal distension model.. Neurogastroenterol Motil. 2008;20(7):843-850.
98. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders.. Gastroenterology. 1996;111(6):1683-1699.
99. Khan WI, Collins SM. Gut motor inflammation: immunological control in enteric infection and inflammation. Clin Exp Immunol. 2005;143(3):389-397.
100. Martin F-P J, Verdu E F, Yang Y, et al. Transgenomic metabolic interactions in a mouse model: interaction of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation.. J Proteome Res. 2006;5(9):2185-2193.
101. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation signifcantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled trial.. Aliment Pharmcol Ther. 2009;29(1):97-103.
102. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome.. Dig Dis Sci. 2008;53(10):2714-2718.
103. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-1049.
104. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
105. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium inflantis 35624 in women with irritable bowel syndrome.. Am J Gastroenterol. 2006;101(7):326-333.
106. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double-blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.. Gastroenterol Clin Biol. 2008;32(2):147-152.
107. Simrén M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study.. Aliment Pharmacol Ther. 2010;31(2):218-227.
108. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915- 1920.
109. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070-11075.
110. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
111. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
112. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190-195.
113. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723.
114. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.. Proc Natl Acad Sci U S A. 2006;103(33):12511-12516.
115. Wang Z, Klipfell E, Bennett BJ, et al. Gut fora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.
116. Rak K, Rader DJ. Cardiovascular disease: the diet-microbe morbid union. Nature. 2011;472(7341):40-41.
117. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-185.
118. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691-701.
119. Abu-Shanab A, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8.. Dig Dis Sci. 2011;56(5):1524-1534.